NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,425,002 | $917,727 | $206,732 | $173,072 |
| - Cash | $771,743 | $340,450 | $438,522 | $53,092 |
| + Debt | $448 | $60 | $118 | $164 |
| Enterprise Value | $1,653,707 | $577,337 | -$231,672 | $120,144 |
| Revenue | $45,563 | $14,090 | $102,694 | $0 |
| % Growth | 223.4% | -86.3% | – | – |
| Gross Profit | $45,563 | $14,090 | $102,694 | $0 |
| % Margin | 100% | 100% | 100% | – |
| EBITDA | -$241,486 | -$176,861 | -$22,338 | -$41,369 |
| % Margin | -530% | -1,255.2% | -21.8% | – |
| Net Income | -$241,598 | -$176,937 | -$22,634 | -$41,785 |
| % Margin | -530.3% | -1,255.8% | -22% | – |
| EPS Diluted | -2.56 | -2.15 | -1.11 | -3.34 |
| % Growth | -19.1% | -93.7% | 66.8% | – |
| Operating Cash Flow | -$158,564 | -$141,218 | $10,665 | -$29,512 |
| Capital Expenditures | -$672 | -$24 | -$221 | -$24 |
| Free Cash Flow | -$159,236 | -$141,242 | $10,444 | -$29,536 |